Grail

Grail's 15min chart shows KDJ Death Cross and Bearish Marubozu.

Grail's 15min chart shows MACD Death Cross and Bollinger Bands narrowing.

Grail's 15min Chart Triggers KDJ Death Cross, Bearish Marubozu Pattern Emerges

Grail:Guggenheim Raises PT to $130 from $100, Maintains Buy Rating

Grail's Galleri MCED Test Expected to Drive Growth Amid FDA Submission and Guidance Update

Catalyst<ul> <li>Recent Bullish Engulfing and WR Oversold signals in late November and early December point to rebound momentum for GRAL.</li> <li>Most analysts rate GRAL Buy or Strong Buy, showing broad institutional optimism.</li> <li>The company maintains strong cash reserves relative to market value.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>Fund flows show negative overall trends with large and extra-large orders trending out.</li></ul>

Key Factors

GRAIL submitted the final module of its Premarket Approval (PMA) application to the FDA on Jan 29 2026.

GRAL News